CLINICAL_TRIALS
trial_result
· 2024-12-02
Clinical Trial Update: A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) [Phase 3]
Summary
A Phase 3 study of ustekinumab in Takayasu arteritis was terminated. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Pharmaceutical K.K. | Conditions: Takayasu Arteritis | Phase 3 | Status: TERMINATED | Results posted: 2024-12-02